Neuropsychiatric impact of hepatitis C on advanced HIV

E L Ryan1, S Morgello, K Isaacs

  • 1Departments of Psychiatry, The Mount Sinai Medical Center, New York, NY, USA. elizabeth.ryan@mssm.edu

Neurology
|March 24, 2004
PubMed

Insights

Hepatitis C (HCV) infection appears to worsen central nervous system (CNS) dysfunction in individuals with advanced HIV. This coinfection is linked to poorer neurocognitive performance and increased rates of HIV-associated dementia.

Area of Science:

  • Neuroscience
  • Infectious Diseases
  • Psychiatry

Background:

  • Advanced HIV infection is associated with cognitive impairment.
  • Hepatitis C virus (HCV) coinfection is common in HIV-positive individuals.
  • The impact of HCV on CNS dysfunction in HIV patients requires further investigation.

Purpose of the Study:

  • To determine if HCV coinfection contributes to central nervous system (CNS) dysfunction in individuals with advanced HIV.
  • To compare the neuropsychiatric profiles of HIV+/HCV+ and HIV+/HCV- individuals.

Main Methods:

  • Cross-sectional study design.
  • Neurocognitive testing and psychiatric interviews.
  • Serological testing for HCV and serum chemistries for hepatic function.

Main Results:

  • HIV+/HCV+ individuals showed higher rates of past substance dependence and substance-induced depression.
  • A trend towards worse neurocognitive performance was observed in HIV+/HCV+ participants, particularly in executive functioning and perseveration.
  • Cognitive differences correlated with HCV serology but not liver disease severity.
  • HIV+/HCV+ patients had higher rates of HIV-associated dementia.

Conclusions:

  • HCV coinfection has a detectable neuropsychiatric impact in advanced HIV cohorts.
  • The observed cognitive deficits are linked to HCV, independent of liver disease severity.
  • Further research is warranted to understand the mechanisms underlying HCV's contribution to CNS dysfunction in HIV.
Abstract

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Hepatic Encephalopathy01:29

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...